This Mouse Monoclonal antibody specifically detects TNFSF11 (Denosumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.
Catalog No. ABIN7200656
Quick Overview for Recombinant TNFSF11 (Denosumab Biosimilar) antibody (ABIN7200656)
Target
TNFSF11 (Denosumab Biosimilar)
Antibody Type
Recombinant Antibody
Fragment
Fab fragment
Reactivity
Human
Host
Mouse
Clonality
Monoclonal
Conjugate
This TNFSF11 (Denosumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
Purpose
Denosumab Biosimilar, Human RANKL Monoclonal Antibody
Specificity
The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.
Characteristics
Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
Purification
Protein A or G affinity column
Purity
>95 % by reducing SDS-PAGE
Sterility
0.2 μm filtered
Endotoxin Level
< 1 EU per 1 mg of the protein by the LAL method
Immunogen
The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.
Research Grade
Reactivity: Human
Host: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Application Notes
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
> 3 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Preservative
Without preservative
Storage
4°C,-20 °C
Storage Comment
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.